Dihydrofolate reductase inhibitors as potential drugs.
D000630:Aminopterin / Q000494:pharmacology; D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy; D001692:Biological Transport / Q000187:drug effects; D004347:Drug Interactions; D005492:Folic Acid / Q000494:pharmacology; D005493:Folic Acid Antagonists; D006373:Helminthiasis / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007942:Leukemia, Experimental / Q000201:enzymology; D008099:Liver / Q000201:enzymology; D008727:Methotrexate / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D051379:Mice; D009181:Mycoses / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy; D011528:Protozoan Infections / Q000188:drug therapy; D011565:Psoriasis / Q000188:drug therapy; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D011955:Receptors, Drug / Q000187:drug effects; D014349:Trypanosoma cruzi / Q000201:enzymology
D000962:Antimalarials; D005493:Folic Acid Antagonists; D007166:Immunosuppressive Agents; D011799:Quinazolines; D011955:Receptors, Drug; C013474:2,4-diaminoquinazoline; D005492:Folic Acid; D000630:Aminopterin; D008727:Methotrexate